JP2025525406A - ピリド［４，３－ｄ］ピリミジン化合物 - Google Patents

ピリド［４，３－ｄ］ピリミジン化合物

Info

Publication number
JP2025525406A
JP2025525406A JP2024576355A JP2024576355A JP2025525406A JP 2025525406 A JP2025525406 A JP 2025525406A JP 2024576355 A JP2024576355 A JP 2024576355A JP 2024576355 A JP2024576355 A JP 2024576355A JP 2025525406 A JP2025525406 A JP 2025525406A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024576355A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024009191A5 (enExample
Inventor
コ―ル ディーフォーリスト ジェイコブ
ナガタ アサコ
ポール プランケン サイモン
エリス シュパングラー ジリアン
チャニング サットン スコット
ハワード タトラック ジョン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2025525406A publication Critical patent/JP2025525406A/ja
Publication of JPWO2024009191A5 publication Critical patent/JPWO2024009191A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024576355A 2022-07-05 2023-06-30 ピリド［４，３－ｄ］ピリミジン化合物 Pending JP2025525406A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263358324P 2022-07-05 2022-07-05
US63/358,324 2022-07-05
US202263394338P 2022-08-02 2022-08-02
US63/394,338 2022-08-02
US202263414939P 2022-10-11 2022-10-11
US63/414,939 2022-10-11
US202363502931P 2023-05-18 2023-05-18
US63/502,931 2023-05-18
PCT/IB2023/056844 WO2024009191A1 (en) 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2025525406A true JP2025525406A (ja) 2025-08-05
JPWO2024009191A5 JPWO2024009191A5 (enExample) 2025-10-03

Family

ID=87426656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024576355A Pending JP2025525406A (ja) 2022-07-05 2023-06-30 ピリド［４，３－ｄ］ピリミジン化合物

Country Status (16)

Country Link
EP (1) EP4551296A1 (enExample)
JP (1) JP2025525406A (enExample)
KR (1) KR20250029954A (enExample)
CN (1) CN119585286A (enExample)
AU (1) AU2023302139A1 (enExample)
CA (1) CA3261000A1 (enExample)
CL (1) CL2024003699A1 (enExample)
CO (1) CO2024016875A2 (enExample)
CR (1) CR20240556A (enExample)
DO (1) DOP2024000275A (enExample)
IL (1) IL317957A (enExample)
MA (1) MA71388A (enExample)
MX (1) MX2024015001A (enExample)
PE (1) PE20250259A1 (enExample)
TW (2) TW202513571A (enExample)
WO (1) WO2024009191A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
KR20240163107A (ko) 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
CN120282969A (zh) * 2022-11-17 2025-07-08 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20250165440A (ko) 2023-04-05 2025-11-25 화이자 인코포레이티드 피리도[4,3-d]피리미딘 화합물
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
TW202509040A (zh) * 2023-05-16 2025-03-01 大陸商和記黃埔醫藥（上海）有限公司 三環類化合物及其用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins
WO2025130912A1 (zh) * 2023-12-19 2025-06-26 正大天晴药业集团股份有限公司 三并环类化合物及其医药用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2020221239A1 (zh) * 2019-04-28 2020-11-05 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
JP2024534610A (ja) * 2021-09-27 2024-09-20 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 多環式縮合環誘導体およびその利用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SG186656A1 (en) 2007-12-14 2013-01-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
BR112014007203A2 (pt) 2011-09-27 2017-06-13 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
MX2017013297A (es) 2015-04-13 2018-06-19 Pfizer Anticuerpos terapeuticos y sus usos.
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CN110191662A (zh) 2016-11-16 2019-08-30 温克机器人技术公司 用于美容院的机器
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
TWI757499B (zh) 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
JP7622043B2 (ja) 2019-08-29 2025-01-27 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
IL303446A (en) * 2020-12-15 2023-08-01 Mirati Therapeutics Inc Azaquinazoline compounds as PAN-KRas inhibitors
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2020221239A1 (zh) * 2019-04-28 2020-11-05 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
JP2024534610A (ja) * 2021-09-27 2024-09-20 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 多環式縮合環誘導体およびその利用

Also Published As

Publication number Publication date
MA71388A (fr) 2025-04-30
CL2024003699A1 (es) 2025-04-11
CO2024016875A2 (es) 2024-12-19
PE20250259A1 (es) 2025-01-29
KR20250029954A (ko) 2025-03-05
WO2024009191A1 (en) 2024-01-11
CN119585286A (zh) 2025-03-07
CR20240556A (es) 2025-01-29
AU2023302139A1 (en) 2024-12-19
MX2024015001A (es) 2025-01-09
IL317957A (en) 2025-02-01
EP4551296A1 (en) 2025-05-14
CA3261000A1 (en) 2024-01-11
TWI869913B (zh) 2025-01-11
DOP2024000275A (es) 2025-01-31
TW202513571A (zh) 2025-04-01
TW202409047A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
JP2025525406A (ja) ピリド［４，３－ｄ］ピリミジン化合物
AU2020200407B2 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP2024147561A (ja) ３－（５－ヒドロキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
EP4301363A1 (en) Quinazoline amine derivatives as kras inhibitors
US12281127B2 (en) Pyrido[4,3-d]pyrimidine compounds
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TWI755788B (zh) 類鐸受體促效劑
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) Pyrido[4,3-d]pyrimidine compounds
JP2021535909A (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト化合物
JP7584802B2 (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト
JP2019508368A (ja) コルチスタチン類縁体及びその使用
WO2024105563A1 (en) Substituted bicyclic pyridone derivatives
WO2024003773A1 (en) 2,7-naphthyridine compounds as mastl inhibitors
JP2025100453A (ja) ピリド［４，３－ｄ］ピリミジン化合物
KR20250100539A (ko) 피리도[4,3-d]피리미딘 화합물
US20240140947A1 (en) Compound for the treatment of cancer
WO2025094035A1 (en) Toll-like receptor agonists and conjugates thereof
US20190062340A1 (en) Cortistatin analogs
WO2024074977A1 (en) Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
HK40072488A (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250925

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104